We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+32.7%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.21B
AUM Growth
+$566M
Cap. Flow
+$396M
Cap. Flow %
32.65%
Top 10 Hldgs %
61.2%
Holding
106
New
26
Increased
22
Reduced
28
Closed
20

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$20.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19M
3
NVS icon
Novartis
NVS
+$17.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.6M
5
NVO
Novo Nordisk
NVO
+$10.5M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$24.8M
2
ARQL
Arqule Inc
ARQL
+$20.7M
3
GILD icon
Gilead Sciences
GILD
+$13.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 52.36%
2 Technology 6.25%
3 Industrials 0.98%
4 Consumer Discretionary 0.93%
5 Communication Services 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SEDG icon
51
SolarEdge
SEDG
$2.51B
$5.4M 0.45%
56,822
-7,180
-11% -$614K
CSTE icon
52
Caesarstone
CSTE
$72.3M
$5.34M 0.44%
354,357
-107,152
-23% -$1.72M
NEOS
53
DELISTED
Neos Therapeutics, Inc
NEOS
$5.33M 0.44%
3,530,731
-377,534
-10% -$566K
WIX icon
54
WIX.com
WIX
$2.3B
$5.07M 0.42%
41,415
+4,525
+12% +$554K
RARE icon
55
Ultragenyx Pharmaceutical
RARE
$2.45B
$4.91M 0.4%
+115,000
New +$4.74M
KRYS icon
56
Krystal Biotech
KRYS
$10.1B
$4.78M 0.39%
86,280
-31,345
-27% -$1.54M
PRNB
57
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$4.74M 0.39%
+86,500
New +$3.23M
VKTX icon
58
Viking Therapeutics
VKTX
$3.7B
$4.73M 0.39%
+590,000
New +$4.3M
NGNE icon
59
Neurogene
NGNE
$656M
$4.68M 0.39%
+19,000
New +$1.89M
TVTX icon
60
Travere Therapeutics
TVTX
$5.2B
$4.51M 0.37%
317,381
-12,822
-4% -$164K
FSCT
61
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
$4.49M 0.37%
137,021
-36,675
-21% -$1.2M
BURL icon
62
Burlington
BURL
$23.2B
$4.45M 0.37%
19,500
– –
PTGX icon
63
Protagonist Therapeutics
PTGX
$8.79B
$4.44M 0.37%
+630,000
New +$6.26M
KRNT icon
64
Kornit Digital
KRNT
$705M
$3.48M 0.29%
101,759
-29,829
-23% -$989K
NVMI
65
Nova
NVMI
$12.4B
$3.46M 0.29%
91,466
+39,517
+76% +$1.39M
WAB icon
66
Wabtec
WAB
$49.1B
$3.11M 0.26%
40,000
– –
CYTK icon
67
Cytokinetics
CYTK
$10.5B
$2.85M 0.24%
+268,747
New +$2.76M
ARGX icon
68
argenx
ARGX
$53.4B
$2.66M 0.22%
16,581
-22,000
-57% -$2.98M
KALV
69
DELISTED
KalVista Pharmaceuticals
KALV
$2.63M 0.22%
+147,700
New +$1.93M
TEVA icon
70
Teva Pharmaceuticals
TEVA
$40.8B
$2.55M 0.21%
+260,352
New +$2.32M
ALNA
71
DELISTED
Allena Pharmaceuticals
ALNA
$2.51M 0.21%
917,800
+243,919
+36% +$801K
IMVTU
72
DELISTED
Immunovant, Inc. Units
IMVTU
$2.49M 0.21%
+100,000
New +$2.15M
ABEO icon
73
Abeona Therapeutics
ABEO
$366M
$2.36M 0.19%
+28,819
New +$2.03M
ARYAU
74
DELISTED
ARYA Sciences Acquisiton Corp. Unit
ARYAU
$2.3M 0.19%
200,000
– –
ADMA icon
75
ADMA Biologics
ADMA
$1.96B
$2.16M 0.18%
+540,000
New +$2.35M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2019 Portfolio in Review

As of Q4 2019, Sphera Funds Management held 106 positions worth $1.21B, up 87% from $647M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Sphera Funds Management deployed $396M of net new capital in Q4 2019, opening 26 new positions and adding to 22 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 251,382 shares worth $21.3M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 74% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Arqule Inc, an estimated $20.7M trimmed.

  • Sphera Funds Management's largest Q4 2019 buy was BioMarin Pharmaceuticals: 251,382 shares worth $21.3M.
  • Sphera Funds Management added most to Sanofi in Q4 2019, an estimated $20.6M increase.
  • Sphera Funds Management's biggest Q4 2019 reduction was Arqule Inc, cutting an estimated $20.7M.
  • Sphera Funds Management fully exited Celgene Corp in Q4 2019, selling an estimated $24.8M.
  • Sphera Funds Management's ten largest holdings make up 61% of its $1.21B portfolio in Q4 2019.
  • Sphera Funds Management opened 26 new positions and closed 20 in Q4 2019.
  • Sphera Funds Management's portfolio value rose 87% quarter-over-quarter to $1.21B.

Based on Sphera Funds Management's 13F filing for Q4 2019, filed 13 Feb 2020.